These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 16397250)

  • 21. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
    Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
    J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.
    Martin MJ; Melnyk N; Pollard M; Bowden M; Leong H; Podor TJ; Gleave M; Sorensen PH
    Mol Cell Biol; 2006 Mar; 26(5):1754-69. PubMed ID: 16478996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
    Ota H; Tokunaga E; Chang K; Hikasa M; Iijima K; Eto M; Kozaki K; Akishita M; Ouchi Y; Kaneki M
    Oncogene; 2006 Jan; 25(2):176-85. PubMed ID: 16170353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor.
    Jones RA; Campbell CI; Petrik JJ; Moorehead RA
    Mol Cancer Res; 2008 May; 6(5):819-28. PubMed ID: 18505926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone.
    McTavish H; Griffin RJ; Terai K; Dudek AZ
    Transl Res; 2009 Jun; 153(6):275-82. PubMed ID: 19446281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
    Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway.
    Pang Y; Zheng B; Fan LW; Rhodes PG; Cai Z
    Glia; 2007 Aug; 55(11):1099-107. PubMed ID: 17577243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
    Fang J; Zhou Q; Shi XL; Jiang BH
    Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
    Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
    Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.
    Spruce BA; Campbell LA; McTavish N; Cooper MA; Appleyard MV; O'Neill M; Howie J; Samson J; Watt S; Murray K; McLean D; Leslie NR; Safrany ST; Ferguson MJ; Peters JA; Prescott AR; Box G; Hayes A; Nutley B; Raynaud F; Downes CP; Lambert JJ; Thompson AM; Eccles S
    Cancer Res; 2004 Jul; 64(14):4875-86. PubMed ID: 15256458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor.
    Shen WH; Zhou JH; Broussard SR; Freund GG; Dantzer R; Kelley KW
    Cancer Res; 2002 Aug; 62(16):4746-56. PubMed ID: 12183434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor 1 receptors.
    Chen H; Yan GC; Gishizky ML
    Cell Growth Differ; 1998 Nov; 9(11):939-47. PubMed ID: 9831246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.